Infinity Pharmaceuticals (Infinity Pharmaceuticals) Days Payable : 445.49 (As of Jun. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Infinity Pharmaceuticals Days Payable?

Infinity Pharmaceuticals's average Accounts Payable for the three months ended in Jun. 2023 was $1.72 Mil. Infinity Pharmaceuticals's Cost of Goods Sold for the three months ended in Jun. 2023 was $0.35 Mil. Hence, Infinity Pharmaceuticals's Days Payable for the three months ended in Jun. 2023 was 445.49.

The historical rank and industry rank for Infinity Pharmaceuticals's Days Payable or its related term are showing as below:

INFIQ' s Days Payable Range Over the Past 10 Years
Min: 70.37 Med: 810.07 Max: 4380
Current: 547.01

During the past 13 years, Infinity Pharmaceuticals's highest Days Payable was 4380.00. The lowest was 70.37. And the median was 810.07.

INFIQ's Days Payable is not ranked
in the Biotechnology industry.
Industry Median: 148.01 vs INFIQ: 547.01

Infinity Pharmaceuticals's Days Payable increased from Jun. 2022 (420.65) to Jun. 2023 (445.49). It may suggest that Infinity Pharmaceuticals delayed paying its suppliers.

Infinity Pharmaceuticals Days Payable Historical Data

The historical data trend for Infinity Pharmaceuticals's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Infinity Pharmaceuticals Days Payable Chart

Infinity Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Days Payable

Get a 7-Day Free Trial

4,380.00

70.37

810.07

863.94

785.23

Infinity Pharmaceuticals Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Days Payable	Get a 7-Day Free Trial															420.65	400.42	886.97	655.92	445.49

Competitive Comparison of Infinity Pharmaceuticals's Days Payable

For the Biotechnology subindustry, Infinity Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Infinity Pharmaceuticals's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Infinity Pharmaceuticals's Days Payable distribution charts can be found below:

* The bar in red indicates where Infinity Pharmaceuticals's Days Payable falls into.

Infinity Pharmaceuticals Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Infinity Pharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2022 is calculated as

	Days Payable (A: Dec. 2022 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2021 )	+	Accounts Payable (A: Dec. 2022 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2022 )	*	Days in Period
=	( (2.32	+	4.405)	/	2 )	/	1.563	*	365
=	3.3625					/	1.563	*	365
=	785.23

Infinity Pharmaceuticals's Days Payable for the quarter that ended in Jun. 2023 is calculated as:

	Days Payable (Q: Jun. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Mar. 2023 )	+	Accounts Payable (Q: Jun. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Jun. 2023 )	*	Days in Period
=	( (1.935	+	1.502)	/	2 )	/	0.352	*	365 / 4
=	1.7185					/	0.352	*	365 / 4
=	445.49

Infinity Pharmaceuticals Days Payable Related Terms

Thank you for viewing the detailed overview of Infinity Pharmaceuticals's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Infinity Pharmaceuticals (Infinity Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infinity Pharmaceuticals Inc (OTCPK:INFIQ) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

1100 Massachusetts Avenue, Floor 4, Cambridge, MA, USA, 02138

Website

https://www.infi.com

Infinity Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of specific cancers. The company's developed products and those under development include therapies targeting hematologic malignancies, or blood cancers; refractory indolent non-Hodgkin lymphoma; refractory chronic lymphocytic leukemia; and solid tumors, including melanoma and non-small cell lung cancer. Infinity has a strategic partnership with AbbVie to develop some of its oncology related treatments. The company operates in only one segment which is drug development.

Executives

Adelene Q Perkins	director, officer: President & CEO	C/O INFINITY PHARMACEUTICALS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Stephane Peluso	officer: Chief Scientific Officer	1100 MASSACHUSETTS AVENUE, CAMBRIDGE MA 02138
Brian Schwartz	director	C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Robert Jr. Ilaria	officer: Chief Medical Officer	1100 MASSACHUSETTS AVENUE, 4TH FLOOR, CAMBRIDGE MA 02138
Biotechnology Value Fund L P	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc	other: See Explanation of Responses	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc	other: See Explanation of Responses	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Richard Gaynor	director	C/O NEON THERAPEUTICS, 40 ERIE STREET, SUITE 110, CAMBRIDGE MA 02139
Jeffery Kutok	officer: Chief Scientific Officer	784 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Samuel Agresta	officer: Chief Medical Officer	784 MEMORIAL DR., CAMBRIDGE MA 02139
David W Beier	director	AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Lawrence E Bloch	officer: EVP, CFO & CBO
Michael Kauffman	director	C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, SECOND FLOOR, NEWTON MA 02459
Michael C Venuti	director